Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.
Evans J, Chapple A, Salisbury H, Corrie P, Ziebland S. “It can’t be very important because it comes and goes”–patients’ accounts of intermittent symptoms preceding a pancreatic cancer diagnosis: a qualitative study. BMJ Open. 2014;4(2): e004215. https://doi.org/10.1136/bmjopen-2013-004215.
Article PubMed PubMed Central Google Scholar
Adamska A, Elaskalani O, Emmanouilidi A, Kim M, Abdol Razak NB, Metharom P, et al. Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Adv Biol Regul. 2018;68:77–87. https://doi.org/10.1016/j.jbior.2017.11.007.
CAS Article PubMed Google Scholar
Murakami T, Hiroshima Y, Matsuyama R, Homma Y, Hoffman RM, Endo I. Role of the tumor microenvironment in pancreatic cancer. Ann Gastroenterol Surg. 2019;3(2):130–7. https://doi.org/10.1002/ags3.12225.
Article PubMed PubMed Central Google Scholar
Andrén-Sandberg A. Pancreatic cancer: chemotherapy and radiotherapy. N Am J Med Sci. 2011;3(1):1–12. https://doi.org/10.4297/najms.2011.31.
Article PubMed PubMed Central Google Scholar
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. https://doi.org/10.1056/NEJMoa1011923.
CAS Article PubMed Google Scholar
Vreeland TJ, McAllister F, Javadi S, Prakash LR, Fogelman DR, Ho L, et al. Benefit of gemcitabine/nab-paclitaxel rescue of patients with borderline resectable or locally advanced pancreatic adenocarcinoma after early failure of FOLFIRINOX. Pancreas. 2019;48(6):837–43. https://doi.org/10.1097/MPA.0000000000001345.
CAS Article PubMed PubMed Central Google Scholar
Cavanna L, Stroppa EM, Citterio C, Mordenti P, Di Nunzio C, Peveri S, et al. Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience. Onco Targets Ther. 2019;12:3077–85. https://doi.org/10.2147/ott.s200754.
Yang F, Jin C, Fu DL, Warshaw AL. Modified FOLFIRINOX for resected pancreatic cancer: opportunities and challenges. World J Gastroenterol. 2019;25(23):2839–45. https://doi.org/10.3748/wjg.v25.i23.2839.
Article PubMed PubMed Central Google Scholar
Ueno H, Kosuge T. Adjuvant treatments for resectable pancreatic cancer. J Hepatobiliary Pancreat Surg. 2008;15(5):468–72. https://doi.org/10.1007/s00534-008-1357-3.
Abbassi R, Algül H. Palliative chemotherapy in pancreatic cancer-treatment sequences. Transl Gastroenterol Hepatol. 2019;4:56. https://doi.org/10.21037/tgh.2019.06.09.
Article PubMed PubMed Central Google Scholar
Riedl JM, Posch F, Horvath L, Gantschnigg A, Renneberg F, Schwarzenbacher E, et al. Gemcitabine/nab-paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: a propensity score analysis. Eur J Cancer. 2021;151:3–13. https://doi.org/10.1016/j.ejca.2021.03.040.
CAS Article PubMed Google Scholar
Niu J, Straubinger RM, Mager DE. Pharmacodynamic drug-drug interactions. Clin Pharmacol Ther. 2019;105(6):1395–406. https://doi.org/10.1002/cpt.1434.
Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3(3): e00149. https://doi.org/10.1002/prp2.149.
Article PubMed PubMed Central Google Scholar
Molins EAG, Jusko WJ. Assessment of three-drug combination pharmacodynamic interactions in pancreatic cancer cells. Aaps j. 2018;20(5):80. https://doi.org/10.1208/s12248-018-0235-4.
CAS Article PubMed Google Scholar
Mager DE, Jusko WJ. Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2008;83(6):909–12. https://doi.org/10.1038/clpt.2008.52.
CAS Article PubMed Google Scholar
Zimmer A, Katzir I, Dekel E, Mayo AE, Alon U. Prediction of multidimensional drug dose responses based on measurements of drug pairs. Proc Natl Acad Sci U S A. 2016;113(37):10442–7. https://doi.org/10.1073/pnas.1606301113.
CAS Article PubMed PubMed Central Google Scholar
Nelson SR, Zhang C, Roche S, O’Neill F, Swan N, Luo Y, et al. Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development. Sci Rep. 2020;10(1):2778. https://doi.org/10.1038/s41598-020-59368-7.
CAS Article PubMed PubMed Central Google Scholar
Hou S, Tiriac H, Sridharan BP, Scampavia L, Madoux F, Seldin J, et al. Advanced development of primary pancreatic organoid tumor models for high-throughput phenotypic drug screening. SLAS Discov. 2018;23(6):574–84. https://doi.org/10.1177/2472555218766842.
CAS Article PubMed PubMed Central Google Scholar
Ande A, Vaidya TR, Tran BN, Vicchiarelli M, Brown AN, Ait-Oudhia S. Utility of a Novel three-dimensional and dynamic (3DD) cell culture system for PK/PD studies: evaluation of a triple combination therapy at overcoming anti-HER2 Treatment resistance in breast cancer. Front Pharmacol. 2018;9:403. https://doi.org/10.3389/fphar.2018.00403.
CAS Article PubMed PubMed Central Google Scholar
Roche S, O’Neill F, Murphy J, Swan N, Meiller J, Conlon NT, et al. Establishment and characterisation by expression microarray of patient-derived xenograft panel of human pancreatic adenocarcinoma patients. Int J Mol Sci. 2020;21(3). https://doi.org/10.3390/ijms21030962.
Martin A, Clynes M. Comparison of 5 microplate colorimetric assays for in vitro cytotoxicity testing and cell proliferation assays. Cytotechnology. 1993;11(1):49–58. https://doi.org/10.1007/bf00749057.
CAS Article PubMed Google Scholar
Y. Di Veroli G, Fornari C, Wang D, Mollard Sv, Bramhall JL, M. Richards F, et al. Combenefit: an interactive platform for the analysis and visualisation of drug combinations. Bioinformatics. 2016;32 2866–8.
Bliss CI. The toxicity of poisons applied jointly. Annals of Applied Biology1939. p. 585–615.
Webb JL. Effect of more than one inhibitor. Enzyme and Metabolic Inhibitors1963. p. 66–79.
Bruckner HW, Spigelman M. Leucovorin as a clinical potentiator of 5-fluorouracil toxicity and anticancer efficacy. Mt Sinai J Med. 1988;55(5):390–4.
Showalter SL, Showalter TN, Witkiewicz A, Havens R, Kennedy EP, Hucl T, et al. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol Ther. 2008;7(7):986–94. https://doi.org/10.4161/cbt.7.7.6181.
Harrison RL. Introduction to Monte Carlo simulation. AIP Conf Proc. 2010;1204:17–21. https://doi.org/10.1063/1.3295638.
CAS Article PubMed PubMed Central Google Scholar
Chowbay B XJ, Wong JXG, Marvalim C, Ng SL, Sutiman N, Leong WF. Effects of oxaliplatin, capecitabine and irinotecan (OXIRI) on PDAC cell lines carrying different Kras mutational status ASCO annual meeting: Journal of Clinical Oncology; 2016.
Kim Y, Han D, Min H, Jin J, Yi EC. Comparative proteomic profiling of pancreatic ductal adenocarcinoma cell lines. Mol Cells. 2014;37(12):888–98. https://doi.org/10.14348/molcells.2014.0207.
CAS Article PubMed PubMed Central Google Scholar
Peters GJ, van Groeningen CJ, van der Wilt CL, Meijer S, Smid K, Laurensse E, et al. Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin. Semin Oncol. 1992;19(2 Suppl 3):26–35.
Van der Wilt CL, Pinedo HM, Smid K, Peters GJ. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res. 1992;52(18):4922–8.
Tsujimoto H, Tsukioka S, Ono S, Sakamoto E, Sakamoto K, Tsuta K, et al. Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase. Oncol Lett. 2010;1(6):973–80. https://doi.org/10.3892/ol.2010.172.
CAS Article PubMed PubMed Central Google Scholar
Sakamoto E, Tsukioka S, Oie S, Kobunai T, Tsujimoto H, Sakamoto K, et al. Folylpolyglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity. Biochem Biophys Res Commun. 2008;365(4):801–7. https://doi.org/10.1016/j.bbrc.2007.11.043.
CAS Article PubMed Google Scholar
Nakamura A, Nakajima G, Okuyama R, Kuramochi H, Kondoh Y, Kanemura T, et al. Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase. Gastric Cancer. 2014;17(1):188–95. https://doi.org/10.1007/s10120-013-0249-7.
CAS Article PubMed Google Scholar
Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res. 1999;5(5):1189–96.
Lei F, Xi X, Rachagani S, Seshacharyulu P, Talmon GA, Ponnusamy MP, et al. Nanoscale platform for delivery of active IRINOX to combat pancreatic cancer. J Control Release. 2021;330:1229–43. https://doi.org/10.1016/j.jconrel.2020.11.029.
CAS Article PubMed Google Scholar
Deer EL, González-Hernández J, Coursen JD, Shea JE, Ngatia J, Scaife CL, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010;39(4):425–35. https://doi.org/10.1097/MPA.0b013e3181c15963.
CAS Article PubMed PubMed Central Google Scholar
Yao J, Cai HH, Wei JS, An Y, Ji ZL, Lu ZP, et al. Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells. Oncol Rep. 2010;23(5):1375–82. https://doi.org/10.3892/or_00000774.
CAS Article PubMed Google Scholar
Rao CV, Mohammed A. New insights into pancreatic cancer stem cells. World J Stem Cells. 2015;7(3):547–55. https://doi.org/10.4252/wjsc.v7.i3.547.
Article PubMed PubMed Central Google Scholar
Qin B, Tanaka R, Shibata Y, Arita S, Ariyama H, Kusaba H, et al. In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines. Anticancer Drugs. 2006;17(4):445–53. https://doi.org/10.1097/01.cad.0000198912.98442.cd.
留言 (0)